Showing 6801-6810 of 8840 results for "".
- FDA Approves New Tralokinumab-ldrm Autoinjectorhttps://practicaldermatology.com/news/fda-approves-new-tralokinumab-ldrm-autoinjector/2467047/The US Food and Drug Administration (FDA) announced the approval of a new tralokinumab-ldrm 300-mg single-dose autoinjector for adult patients. Adbry® (LEO Pharma Inc.), a high-affinity fully human monoclonal antibody, is currently indicated in the US for the treatment of moderate-to-sever
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://practicaldermatology.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://practicaldermatology.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Moderate-to-Severe AA Linked to AD Comorbidityhttps://practicaldermatology.com/news/moderate-severe-aa-linked-ad-comorbidity/2467042/Patients with moderate-to-severe alopecia areata (AA) had higher prevalence and incidence of atopic dermatitis (AD) comorbidity and higher prevalence of moderate-to-severe AD than those with mild AA in a study presented this month at the Revolutionizing Alopecia, Vitligo, and Eczema (RAVE) Confer
- Sustained Efficacy Following Treatment With Lebrikizumabhttps://practicaldermatology.com/news/sustained-efficacy-following-treatment-lebrikizumab/2467017/A subset of moderate-to-severe atopic dermatitis (AD) patients who were randomly withdrawn from lebrikizumab maintained a stable EASI 90 response up to Week 52 with negligible remaining lebrikizumab serum concentrations, according to research presented at the Revolutionizing Atopic Dermatitis (RA
- INTEGUMENT-OLE: Efficacy and Safety of Roflumilast Cream 0.15% in AD Maintained to 56 Weekshttps://practicaldermatology.com/news/integument-ole-efficacy-and-safety-roflumilast-cream-ad-maintained-56-weeks/2467010/Results from the INTEGUMENT-OLE long-term study suggested that roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) is effective and well-tolerated over a treatment period of up to 56 weeks in adults and children aged six years and older. Researchers for the open-label study
- FDA Gives Green Light to InnoCare's Clinical Trial of TYK2 Inhibitor ICP-332 for ADhttps://practicaldermatology.com/news/fda-gives-green-light-innocares-clinical-trial-tyk2-inhibitor-icp-332-ad/2467004/InnoCare Pharma announced that the FDA has cleared its investigational new drug (IND) application for its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332. ICP-332 is a potent and selective TYK2 inhibitor. It achieved multiple efficacy endpoints in the China phase 2 study for the treatmen
- FDA Takes Key Step on Tapinarof for ADhttps://practicaldermatology.com/news/fda-takes-key-step-tapinarof-ad/2467002/The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData. Tapinarof, an aryl hydrocar
- FDA-Cleared Fractional Laser for Hair Loss Now Availablehttps://practicaldermatology.com/news/fda-cleared-fractional-laser-hair-loss-now-available/2467000/The only US Food and Drug Administration-cleared fractional laser for safe, effective, and natural hair loss treatment is now available on the US market with the launch of FoLix from Lumenis Be. Ltd. Utilizing fractional laser and proprietary technology tailored for hair, FoLix offers res
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l